Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balstilimab Alone or with Zalifrelimab in Advanced Cervical Cancer
NCT05033132Phase 2Withdrawn
- Sponsor
- Agenus Inc.
- Start
- Oct 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of balstilimab in Cervical Cancer (CC), sponsored by Agenus Inc.. Planned start Oct 2021; status: withdrawn.
02
Drugs
balstilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05033132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033132.